Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration

Meng Hsiu Yen, Yhu Chering Huang, Min Chi Chen, Ching Chuan Liu, Nan Chang Chiu, Reyin Lien, Luan Yin Chang, Cheng Hsun Chiu, Kuo Chien Tsao, Tzou Yien Lin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: The benefits of intravenous immunoglobulin (IVIG) therapy for severe neonatal enterovirus infections are still controversial. Object: To evaluate whether timing of IVIG administration might affect clinical outcomes of neonates with severe enteroviral infections. Study designs: We retrospectively analyzed 67 neonates with culture-confirmed severe enteroviral infection, defined as hepatitis with coagulopathy and thrombocytopenia. Clinical features, outcomes and the usage of IVIG therapy were collected and analyzed. IVIG administered within 3 days of illness onset was classified as early IVIG therapy. Results: Of the 67 cases, 38 (57%) were male, 27 (40%) were premature, 57 (85%) had disease onset within 7 days of life and all but 2 cases were caused by coxsackievirus B group. Ten infants (15%) had clinically evident myocarditis. 41 infants (61%) received IVIG therapy and 29 were early IVIG therapy. Fifteen infants (22%) eventually died, without IVIG therapy for 7 infants. The deceased had a significantly higher peak serum aspartate aminotransferase (AST) level than the survivors (3539 vs. 866. IU/L, p<. 0.01). The timing of IVIG therapy was highly correlated with the timing of peak AST level in patients with early IVIG therapy. Multiple logistic regression analysis showed that a higher nadir hemoglobin level (adjusted odds ratio 2.8, 95% confidence interval: 1.4-5.4), no concurrent myocarditis (42.6 [3.4-5289]) and early IVIG therapy (14.7 [1.3-163]) were independently associated with a favorable prognosis. Conclusions: In defined severe neonatal enterovirus infections, serum AST level correlated with the disease severity. Early IVIG therapy, if needed, may be beneficial for survival.

Original languageEnglish
Pages (from-to)92-96
Number of pages5
JournalJournal of Clinical Virology
Volume64
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Passive Immunization
Newborn Infant
Infection
Aspartate Aminotransferases
Enterovirus Infections
Myocarditis
Human Enterovirus B
Sick Leave
Serum
Thrombocytopenia
Intravenous Administration
Hepatitis
Survivors
Hemoglobins
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals

Keywords

  • Enterovirus
  • Hepatitis
  • Intravenous immunoglobulin
  • Myocarditis
  • Neonates

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Medicine(all)

Cite this

Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. / Yen, Meng Hsiu; Huang, Yhu Chering; Chen, Min Chi; Liu, Ching Chuan; Chiu, Nan Chang; Lien, Reyin; Chang, Luan Yin; Chiu, Cheng Hsun; Tsao, Kuo Chien; Lin, Tzou Yien.

In: Journal of Clinical Virology, Vol. 64, 01.03.2015, p. 92-96.

Research output: Contribution to journalArticle

Yen, Meng Hsiu ; Huang, Yhu Chering ; Chen, Min Chi ; Liu, Ching Chuan ; Chiu, Nan Chang ; Lien, Reyin ; Chang, Luan Yin ; Chiu, Cheng Hsun ; Tsao, Kuo Chien ; Lin, Tzou Yien. / Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. In: Journal of Clinical Virology. 2015 ; Vol. 64. pp. 92-96.
@article{db7c2e384c264b00b02453973c0f07a7,
title = "Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration",
abstract = "Background: The benefits of intravenous immunoglobulin (IVIG) therapy for severe neonatal enterovirus infections are still controversial. Object: To evaluate whether timing of IVIG administration might affect clinical outcomes of neonates with severe enteroviral infections. Study designs: We retrospectively analyzed 67 neonates with culture-confirmed severe enteroviral infection, defined as hepatitis with coagulopathy and thrombocytopenia. Clinical features, outcomes and the usage of IVIG therapy were collected and analyzed. IVIG administered within 3 days of illness onset was classified as early IVIG therapy. Results: Of the 67 cases, 38 (57{\%}) were male, 27 (40{\%}) were premature, 57 (85{\%}) had disease onset within 7 days of life and all but 2 cases were caused by coxsackievirus B group. Ten infants (15{\%}) had clinically evident myocarditis. 41 infants (61{\%}) received IVIG therapy and 29 were early IVIG therapy. Fifteen infants (22{\%}) eventually died, without IVIG therapy for 7 infants. The deceased had a significantly higher peak serum aspartate aminotransferase (AST) level than the survivors (3539 vs. 866. IU/L, p<. 0.01). The timing of IVIG therapy was highly correlated with the timing of peak AST level in patients with early IVIG therapy. Multiple logistic regression analysis showed that a higher nadir hemoglobin level (adjusted odds ratio 2.8, 95{\%} confidence interval: 1.4-5.4), no concurrent myocarditis (42.6 [3.4-5289]) and early IVIG therapy (14.7 [1.3-163]) were independently associated with a favorable prognosis. Conclusions: In defined severe neonatal enterovirus infections, serum AST level correlated with the disease severity. Early IVIG therapy, if needed, may be beneficial for survival.",
keywords = "Enterovirus, Hepatitis, Intravenous immunoglobulin, Myocarditis, Neonates",
author = "Yen, {Meng Hsiu} and Huang, {Yhu Chering} and Chen, {Min Chi} and Liu, {Ching Chuan} and Chiu, {Nan Chang} and Reyin Lien and Chang, {Luan Yin} and Chiu, {Cheng Hsun} and Tsao, {Kuo Chien} and Lin, {Tzou Yien}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.jcv.2015.01.013",
language = "English",
volume = "64",
pages = "92--96",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration

AU - Yen, Meng Hsiu

AU - Huang, Yhu Chering

AU - Chen, Min Chi

AU - Liu, Ching Chuan

AU - Chiu, Nan Chang

AU - Lien, Reyin

AU - Chang, Luan Yin

AU - Chiu, Cheng Hsun

AU - Tsao, Kuo Chien

AU - Lin, Tzou Yien

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: The benefits of intravenous immunoglobulin (IVIG) therapy for severe neonatal enterovirus infections are still controversial. Object: To evaluate whether timing of IVIG administration might affect clinical outcomes of neonates with severe enteroviral infections. Study designs: We retrospectively analyzed 67 neonates with culture-confirmed severe enteroviral infection, defined as hepatitis with coagulopathy and thrombocytopenia. Clinical features, outcomes and the usage of IVIG therapy were collected and analyzed. IVIG administered within 3 days of illness onset was classified as early IVIG therapy. Results: Of the 67 cases, 38 (57%) were male, 27 (40%) were premature, 57 (85%) had disease onset within 7 days of life and all but 2 cases were caused by coxsackievirus B group. Ten infants (15%) had clinically evident myocarditis. 41 infants (61%) received IVIG therapy and 29 were early IVIG therapy. Fifteen infants (22%) eventually died, without IVIG therapy for 7 infants. The deceased had a significantly higher peak serum aspartate aminotransferase (AST) level than the survivors (3539 vs. 866. IU/L, p<. 0.01). The timing of IVIG therapy was highly correlated with the timing of peak AST level in patients with early IVIG therapy. Multiple logistic regression analysis showed that a higher nadir hemoglobin level (adjusted odds ratio 2.8, 95% confidence interval: 1.4-5.4), no concurrent myocarditis (42.6 [3.4-5289]) and early IVIG therapy (14.7 [1.3-163]) were independently associated with a favorable prognosis. Conclusions: In defined severe neonatal enterovirus infections, serum AST level correlated with the disease severity. Early IVIG therapy, if needed, may be beneficial for survival.

AB - Background: The benefits of intravenous immunoglobulin (IVIG) therapy for severe neonatal enterovirus infections are still controversial. Object: To evaluate whether timing of IVIG administration might affect clinical outcomes of neonates with severe enteroviral infections. Study designs: We retrospectively analyzed 67 neonates with culture-confirmed severe enteroviral infection, defined as hepatitis with coagulopathy and thrombocytopenia. Clinical features, outcomes and the usage of IVIG therapy were collected and analyzed. IVIG administered within 3 days of illness onset was classified as early IVIG therapy. Results: Of the 67 cases, 38 (57%) were male, 27 (40%) were premature, 57 (85%) had disease onset within 7 days of life and all but 2 cases were caused by coxsackievirus B group. Ten infants (15%) had clinically evident myocarditis. 41 infants (61%) received IVIG therapy and 29 were early IVIG therapy. Fifteen infants (22%) eventually died, without IVIG therapy for 7 infants. The deceased had a significantly higher peak serum aspartate aminotransferase (AST) level than the survivors (3539 vs. 866. IU/L, p<. 0.01). The timing of IVIG therapy was highly correlated with the timing of peak AST level in patients with early IVIG therapy. Multiple logistic regression analysis showed that a higher nadir hemoglobin level (adjusted odds ratio 2.8, 95% confidence interval: 1.4-5.4), no concurrent myocarditis (42.6 [3.4-5289]) and early IVIG therapy (14.7 [1.3-163]) were independently associated with a favorable prognosis. Conclusions: In defined severe neonatal enterovirus infections, serum AST level correlated with the disease severity. Early IVIG therapy, if needed, may be beneficial for survival.

KW - Enterovirus

KW - Hepatitis

KW - Intravenous immunoglobulin

KW - Myocarditis

KW - Neonates

UR - http://www.scopus.com/inward/record.url?scp=84923360351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923360351&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2015.01.013

DO - 10.1016/j.jcv.2015.01.013

M3 - Article

C2 - 25728086

AN - SCOPUS:84923360351

VL - 64

SP - 92

EP - 96

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -